JY BioMed File U.S. Provisional Patent for Novel Gamma Delta T Cell Expansion Technology

April 2025 — Taipei

Ji Yan Biomedical (JY BioMed) announced the filing of a U.S. Provisional Patent Application for a novel method aimed at the optimized expansion and activation of gamma delta T (γδT) cells for immunotherapy applications.

The provisional patent, titled “Method for the Production of Gamma Delta T Cells for Immunotherapy Applications” (Application No. 63/742,633), was officially filed with the United States Patent and Trademark Office (USPTO) on January 7, 2025

The technology describes a proprietary ex vivo process combining selective immunomagnetic enrichment of Vδ2+ γδT cells with a cytokine-optimized culture system. This approach enables robust expansion, high viability, and enhanced functional properties, addressing several critical challenges historically associated with γδT cell-based therapies.

“This patent filing represents a major step in our efforts to innovate in the field of cell therapy,” said Dr. Ethan Shen, CEO of Ji Yan Biomedical. “We are building a strong foundation for next-generation γδT cell immunotherapies.”

The provisional patent filing supports Ji Yan Biomedical’s broader intellectual property strategy to strengthen its innovation pipeline across oncology and immune-related disorders.

About JY BioMed

JY BioMed is a biotechnology company focused on advancing cell-based and exosome-enabled therapies targeting oncology, regenerative medicine, and immunological diseases. The company emphasizes scientific innovation, academic collaboration, and global regulatory excellence.